.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Deloitte
Chinese Patent Office
McKinsey
Citi
US Department of Justice
Argus Health
Baxter
Fish and Richardson

Generated: September 26, 2017

DrugPatentWatch Database Preview

RAPAFLO Drug Profile

« Back to Dashboard

Which patents cover Rapaflo, and when can generic versions of Rapaflo launch?

Rapaflo is a drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in four countries.

The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the silodosin profile page.

Summary for Tradename: RAPAFLO

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list54
Clinical Trials: see list7
Patent Applications: see list276
Drug Prices:see details
DailyMed Link:RAPAFLO at DailyMed

Pharmacology for Tradename: RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for RAPAFLO

Drugname Dosage Strength RLD Submissiondate
silodosinCapsules4 mg and 8 mgRapaflo10/9/2012

International Patent Family for Tradename: RAPAFLO

Country Document Number Estimated Expiration
European Patent Office0600675► Subscribe
Germany69319551► Subscribe
Japan2944402► Subscribe
Germany122010000031► Subscribe
JapanH06220015► Subscribe
Canada2110454► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RAPAFLO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00454Netherlands► SubscribePRODUCT NAME: SILODOSIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/607/001-014EU/1/09/608/001-014 2010290129
C0036France► SubscribePRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129
90028-0.LSweden► SubscribePRODUCT NAME: SILODOSIN ELLER FARMACEUTISKA GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/09/607/001-014 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-01-29" SEGODKNR="EU/1/09/607/001-014 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-01-29" FLAG="L" SPCNR="1090028-0" 20100129
C/GB10/031United Kingdom► SubscribePRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Covington
Chinese Patent Office
US Department of Justice
UBS
Accenture
Cantor Fitzgerald
Julphar
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot